Enhancement of drug cytotoxicity by silicon containing groups

Letters in Drug Design and Discovery

Volumn 3, Issue 1, 2006, Pages 29-34

  Padrón, José M ^a,b,c   Donadel, Osvaldo J ^b,d   León, Leticia G ^b,c   Martín, Tomás ^a,b,e   Martín, Víctor S ^a,b  

^a Red Tematica de Investigacion Cooperativa en Cancer   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^d UNIVERSIDAD NACIONAL DE SAN LUIS   (Argentina)

^e INSTITUTO DE PRODUCTOS NATURALES Y AGROBIOLOGÍA   (Spain)

Author keywords

Antitumor agents; Drug design; Lipophilicity; Silyl ethers; Structure activity relationships

Indexed keywords

ANTINEOPLASTIC AGENT; FUNCTIONAL GROUP; SILICON DERIVATIVE; TETRAHYDROPYRAN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 33645873906     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018006775240944     Document Type: Article

References (27)

1. (a) Polushin, N. N.; Cohen, J. S. Nucl. Acids Res. 1994, 22, 5492-5496;
2. (b) Jones, B. C.; McGuigan, C.; Riley, P. A. Nucl. Acids Res. 1989, 17, 7195-7201.
3. (a) Bergman, A. M.; Kuiper, C. M.; Myhren, F.; Sandvold, M. L.; Hendriks, H. R.; Peters G. J. Nucleosides Nucleotides Nucleic Acids 2004, 23, 1523-1526;
4. (b) Bergman, A. M.; Kuiper, C. M.; Voorn, D. A.; Comijn, E. M.; Myhren, F.; Sandvold, M. L.; Hendriks, H. R.; Peters G. J. Biochem. Pharmacol. 2004, 67, 503-511;
5. (c) Colin, B.; Jones, N. M.; McGuigan, C.; Riley, P. A. Nucleic Acids Res. 1989, 17, 7195-7201.
6. (a) Bergman, A. M.; Kuiper, C. M.; Noordhuis, P.; Smid, K.; Voorn, D. A.; Comijn, E. M.; Myhren, F.; Sandvold, M. L.; Hendriks, H. R.; Fodstad, O.; Breistol, K.; Peters, G. J. Nucleosides Nucleotides Nucleic Acids 2004, 23, 1329-1333;
7. (b) Ali, S. M.; Khan, A. R.; Ahmad, M. U.; Chen, P.; Sheikh, S.; Ahmad, I. Bioorg. Med. Chem. Lett. 2005, 15, 2571-2574.
8. Kokotos, G.; Theodorou V.; Constantinou-Kokotou, V.; Gibbons, W. A.; Roussakis, C. Bioorg. Med. Chem. Lett. 1998, 8, 1525-1530.
9. Souchard, J.-P.; Ha, T. T.; Cros, S.; Johnson, N. P. J. Med. Chem. 1991, 34, 863-864.
10. Srivastava, V.; Negi, A. S.; Kumar, J. K.; Gupta, M. M.; Khanuja, S.P. Bioorg. Med. Chem. 2005, 13, 5892-5908.
11. (a) Di Francesco, A. M.; Riccardi, A. S.; Barone, G.; Rutella, S.; Meco, D.; Frapolli, R.; Zucchetti, M.; D'Incalci, M.; Pisano, C.; Carminati, P.; Riccardi, R. Biochem. Pharmacol. 2005, 70, 1125-1136;
12. (b) De Cesare, M.; Pratesi, G.; Perego, P.; Carenini, N.; Tinelli, S.; Merlini, L.; Penco, S.; Pisano, C.; Bucci, F.; Vesci, L.; Pace, S.; Capocasa, F.; Carminati, P.; Zunino, F. Cancer Res. 2001, 61, 7189-7195.
13. (a) Van Hattum, A. M.; Pinedo, H. M.; Schlüper, H. M. M.; Hausheer, F. H.; Boven, E. Int. J. Cancer 2000, 88 , 260-266;
14. (b) Van Hattum, A. M.; Schlüper, H. M. Hausheer, F. H.; Pinedo, H. M.; Boven, E. Int. J. Cancer 2002, 100, 22-29.
15. Anderson, W.; Kasliwal, R.; Houston, D. M.; Wang, Y.-s.; Narayanan, V. L.; Haugwitz, R. D.; Plowman, J. J. Med. Chem. 1995, 38, 3789-3797.
16. Iovel, I.; Golomba, L.; Zvejniece, L.; Shestakova, I.; Lukevics, E. Chem. Heterocyclic Comp. 2003, 39, 449-454.
17. Dai, W.-M.; Tachi, Y.; Nishimoto, S.-i.; Zhong, X.; Guo, Z. Lett. Drug Des. Discov. 2004, 1, 69-72.
18. Donadel, O. J.; Martín, T.; Martín, V. S.; Villar, J.; Padrón, J. M. Bioorg. Med. Chem. Lett. 2005, 15, 3536-3539.
19. Nicolaou, K. C.; Hwang, C.-K.; Marron, B. E.; DeFress, S. A.; Couladouros, E. A.; Abe, Y.; Carroll, P. J.; Snyder, J. P. J. Am. Chem. Soc. 1990, 112, 3040-3054.
20. Katsuki, T.; Sharpless, K. B. J. Am. Chem. Soc. 1980, 102, 5974-5976.
21. Ando, K. Tetrahedron Lett. 1995, 36, 4105-4108.
22. All intermediates and final products gave satisfactory analytical and spectroscopic data in full accord with their assigned structures.
23. (a) Keepers, Y. P.; Pizao, P. E.; Peters, G. J.; Van Ark-Otte, J.; Winograd, B. Eur. J. Cancer 1991, 27, 897-900;
24. (b) Skehan, P.; Storeng, P.; Scudeiro, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
25. Pure compounds were initially dissolved in DMSO at 400 times the desired final maximum test concentration, i.e. 100 μM. Control cells were exposed to an equivalent concentration of DMSO. Each agent was tested in duplicates at five different tenfold dilutions. Drug incubation times were 48 h, after which cells were precipitated with 25 μL ice-cold 50% (w/v) trichloroacetic acid and fixed for 60 min at 4°C. Then the SRB assay was performed. The optical density (OD) of each well was measured at 490 nm using Bio-Tek's Elx800 NB 96-well plate reader. The percentage growth was calculated at each of the drug concentration levels based on the difference in OD at the start and end of drug exposure. Values were corrected for background OD from wells only containing medium.
26. Software-predicted lipophilicity of the compounds was calculated with the program CLOGP accessible via Internet (www.daylight.com/daycgi/clogp) working with the Hansch-Leo's "fragment constant" method.
27. Machatha, S. G.; Yalkowsky, S. H. Int. J. Pharm. 2005, 294, 185-192.